Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia.
Olanzapine (OLZ) treatment is associated with a high risk of weight gain, and may cause abnormalities in glycolipid metabolism. Therefore, the underlying mechanism of OLZ-related weight gain is needed to clarify but not yet been adequately determined. In recent years, adipocytokines such as leptin,...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4773092?pdf=render |
| _version_ | 1811282041983991808 |
|---|---|
| author | Nobuto Tsuneyama Yutaro Suzuki Kazushi Sawamura Takuro Sugai Naoki Fukui Junzo Watanabe Shin Ono Mami Saito Toshiyuki Someya |
| author_facet | Nobuto Tsuneyama Yutaro Suzuki Kazushi Sawamura Takuro Sugai Naoki Fukui Junzo Watanabe Shin Ono Mami Saito Toshiyuki Someya |
| author_sort | Nobuto Tsuneyama |
| collection | DOAJ |
| description | Olanzapine (OLZ) treatment is associated with a high risk of weight gain, and may cause abnormalities in glycolipid metabolism. Therefore, the underlying mechanism of OLZ-related weight gain is needed to clarify but not yet been adequately determined. In recent years, adipocytokines such as leptin, adiponectin, and tumor necrosis factor (TNF)-α, which play important roles in energy homeostasis, have been suggested as biomarkers of weight gain. Here, we determined if baseline plasma concentrations of leptin, adiponectin, and TNF-α predict weight gain following OLZ treatment.We recruited 31 schizophrenia outpatients (12 men and 19 women, 28.8 ± 10.2 years old) that were unmedicated or on another antipsychotic monotherapy medication. Baseline body mass index (BMI) and plasma levels of leptin, adiponectin, and TNF-α were obtained. All patients started or were switched to OLZ monotherapy for a maximum of 1 year. BMI was also obtained at the endpoint.Mean BMI change following OLZ treatment was 2.1 ± 2.7 kg/m2. BMI change from baseline to endpoint negatively-correlated with baseline leptin levels in female patients (r = -0.514, P = 0.024), but not male patients. Baseline adiponectin or TNF-α levels were not correlated with BMI change.Baseline plasma leptin can have an effect on subsequent weight gain following OLZ treatment in female patients with schizophrenia. |
| first_indexed | 2024-04-13T01:44:29Z |
| format | Article |
| id | doaj.art-a91ccf674676457d944a36c42098e1b1 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T01:44:29Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a91ccf674676457d944a36c42098e1b12022-12-22T03:08:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01113e014951810.1371/journal.pone.0149518Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia.Nobuto TsuneyamaYutaro SuzukiKazushi SawamuraTakuro SugaiNaoki FukuiJunzo WatanabeShin OnoMami SaitoToshiyuki SomeyaOlanzapine (OLZ) treatment is associated with a high risk of weight gain, and may cause abnormalities in glycolipid metabolism. Therefore, the underlying mechanism of OLZ-related weight gain is needed to clarify but not yet been adequately determined. In recent years, adipocytokines such as leptin, adiponectin, and tumor necrosis factor (TNF)-α, which play important roles in energy homeostasis, have been suggested as biomarkers of weight gain. Here, we determined if baseline plasma concentrations of leptin, adiponectin, and TNF-α predict weight gain following OLZ treatment.We recruited 31 schizophrenia outpatients (12 men and 19 women, 28.8 ± 10.2 years old) that were unmedicated or on another antipsychotic monotherapy medication. Baseline body mass index (BMI) and plasma levels of leptin, adiponectin, and TNF-α were obtained. All patients started or were switched to OLZ monotherapy for a maximum of 1 year. BMI was also obtained at the endpoint.Mean BMI change following OLZ treatment was 2.1 ± 2.7 kg/m2. BMI change from baseline to endpoint negatively-correlated with baseline leptin levels in female patients (r = -0.514, P = 0.024), but not male patients. Baseline adiponectin or TNF-α levels were not correlated with BMI change.Baseline plasma leptin can have an effect on subsequent weight gain following OLZ treatment in female patients with schizophrenia.http://europepmc.org/articles/PMC4773092?pdf=render |
| spellingShingle | Nobuto Tsuneyama Yutaro Suzuki Kazushi Sawamura Takuro Sugai Naoki Fukui Junzo Watanabe Shin Ono Mami Saito Toshiyuki Someya Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia. PLoS ONE |
| title | Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia. |
| title_full | Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia. |
| title_fullStr | Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia. |
| title_full_unstemmed | Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia. |
| title_short | Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia. |
| title_sort | effect of serum leptin on weight gain induced by olanzapine in female patients with schizophrenia |
| url | http://europepmc.org/articles/PMC4773092?pdf=render |
| work_keys_str_mv | AT nobutotsuneyama effectofserumleptinonweightgaininducedbyolanzapineinfemalepatientswithschizophrenia AT yutarosuzuki effectofserumleptinonweightgaininducedbyolanzapineinfemalepatientswithschizophrenia AT kazushisawamura effectofserumleptinonweightgaininducedbyolanzapineinfemalepatientswithschizophrenia AT takurosugai effectofserumleptinonweightgaininducedbyolanzapineinfemalepatientswithschizophrenia AT naokifukui effectofserumleptinonweightgaininducedbyolanzapineinfemalepatientswithschizophrenia AT junzowatanabe effectofserumleptinonweightgaininducedbyolanzapineinfemalepatientswithschizophrenia AT shinono effectofserumleptinonweightgaininducedbyolanzapineinfemalepatientswithschizophrenia AT mamisaito effectofserumleptinonweightgaininducedbyolanzapineinfemalepatientswithschizophrenia AT toshiyukisomeya effectofserumleptinonweightgaininducedbyolanzapineinfemalepatientswithschizophrenia |